drugset / Trial / NCT02316444

Strategies for the Prevention of Hepatitis B Among HIV Infected Patients in Uganda

NCT02316444

Non-randomizedSingle-groupOpen-labelPrevention

Summary

The aim of this study is to compare the effectiveness of two vaccination strategies against Hepatitis B virus (HBV) in subjects already infected with human immunodeficiency virus (HIV). Researchers plan to determine the optimal vaccination strategy for achieving protective immunity to HBV infection in HIV-infected adults attending Mulago Hospital's HIV care clinic. Primary objectives are to assess: 1. The role of CD4-cell count and HIV viral loads on the HBV vaccine response. 2. The role of highly active antiretroviral therapy (HAART) on the HBV vaccine response. The secondary objective is to evaluate whether lack of HAART is associated with high rates of loss to follow-up.

Timeline

Start
2015-11
Primary completion
2017-04-28
Completion
2017-04-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Hepatitis B vaccine Vaccine 20 ug Intramuscular